Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-104532
Filing Date
2025-08-07
Accepted
2025-08-07 06:40:22
Documents
57
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q nuvl-20250630.htm   iXBRL 10-Q 2715410
2 EX-31.1 nuvl-ex31_1.htm EX-31.1 17880
3 EX-31.2 nuvl-ex31_2.htm EX-31.2 17889
4 EX-32.1 nuvl-ex32_1.htm EX-32.1 10961
5 EX-32.2 nuvl-ex32_2.htm EX-32.2 9491
6 GRAPHIC img241479796_0.jpg GRAPHIC 173738
  Complete submission text file 0000950170-25-104532.txt   8434152

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nuvl-20250630.xsd EX-101.SCH 845202
60 EXTRACTED XBRL INSTANCE DOCUMENT nuvl-20250630_htm.xml XML 1297750
Mailing Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142 508-446-2272
Nuvalent, Inc. (Filer) CIK: 0001861560 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40671 | Film No.: 251191446
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)